Cell
Volume 5, Issue 3, July 1975, Pages 319-322
Journal home page for Cell

Article
Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells

https://doi.org/10.1016/0092-8674(75)90107-5Get rights and content

Abstract

Butyric acid is an unusually potent inducer of erythroid differentiation in cultured erythroleukemic cells. It is effective at one hundredth the concentration required of dimethylsulfoxide, a most effective inducing agent. Studies using a variety of analogues and metabolites suggest that the structural features of butyric acid are rather stringently required for induction. This effect is considered in view of the fact that butyric acid is a naturally occurring fatty acid, is effective in relatively low concentrations, and is widely used to form derivatives of cAMP.

References (11)

  • M.J. Griffin et al.

    Arch. Biochem. Biophys.

    (1974)
  • J. Ross et al.

    J. Mol. Biol.

    (1974)
  • J.A. Wright

    Exp. Cell Res.

    (1973)
  • C. Friend et al.
  • E. Ginsburg et al.
There are more references available in the full text version of this article.

Cited by (572)

  • Histone deacetylases: A novel class of therapeutic targets for pancreatic cancer

    2022, Biochimica et Biophysica Acta - Reviews on Cancer
  • Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia

    2020, Biochemical Pharmacology
    Citation Excerpt :

    Within the class of short-chain fatty acids, the two most characterized HDACis are sodium 4-phenylbutyrate and valproic acid [37]. The first is derived from sodium butyrate, a prototype compound of the “short-chain fatty acid” family initially reported to induce differentiation in cultured erythroleukemic cells [76] and whose short half-life limits its therapeutic application [1]. Sodium 4-phenylbutyrate shows selective toxicity for leukemia cells against healthy blood cells [77] and underwent a phase II trial for the treatment of pediatric brain tumors (www.clinicaltrials.gov).

  • Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation

    2018, Critical Reviews in Oncology/Hematology
    Citation Excerpt :

    It is interested to note that, inflammatory stimuli enhanced the sensitivity of macrophages to HDAC inhibitors-inducing apoptosis (Tsolmongyn et al., 2013). Therefore, these data collectively indicate that therapeutic administration of HDAC inhibitors suppresses mature monocyte and macrophage differentiation and functions and also induces their apoptosis at inflammation sites (Abe, 2012; Chateauvieux et al., 2011; Choo et al., 2010; Dragunow et al., 2006; Falkenberg and Johnstone, 2014; Gibbons et al., 2011; Grabiec et al., 2012, 2010; Joosten et al., 2011; Laribee and Klemsz, 2001; Leder and Leder, 1975; Lohman et al., 2016; Nasu et al., 2008; Shakespear et al., 2011; Shao et al., 2004; Shein et al., 2009; Shi et al., 2012; Sweet et al., 2012; Toussirot et al., 2013, 2010b; Tsolmongyn et al., 2013; Woan et al., 2012; Zini et al., 2012). Therefore, inducing the apoptosis of pro-inflammatory macrophages and other inflammatory cells at sites of inflammation by HDAC inhibitors may contribute to the therapeutic benefits of these small molecules as anti-inflammatory agents (Fig. 2).

  • Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways

    2018, Pharmacological Research
    Citation Excerpt :

    Notably, it is also present in cheese and butter. Initially, butyrate (11) was described as an unusually potent inducer of erythroid differentiation in cultured erythroleukemic cells [96]. Treatment of cultured leukemia cells with butyrate (11) was then reported to inhibit classes I, IIa and IV HDAC activity, causing rapid histone hyperacetylation in leukemia cells [97].

View all citing articles on Scopus
View full text